Amit Etkin, Alto Neuroscience CEO

Al­to touts new PhI­Ia de­pres­sion da­ta with plans to keep charg­ing for­ward

SAN FRAN­CIS­CO — Pri­vate biotech Al­to Neu­ro­science re­vealed new da­ta Tues­day morn­ing for a psy­chi­atric drug it’s so ex­cit­ed about that a fol­low-up study is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.